- Chemotherapy
- Adjuvant Chemotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy
Gastric Cancer Treatment Market size was valued at USD 9.5 billion in 2023. It is expected to reach USD 25.6 billion by 2028, at a CAGR of 15.3% from 2024 to 2030. Sacral nerve stimulation (SNS) is a therapeutic electrical incitement treatment that is utilized to treat long-haul entrail control and bladder control side effects through the adjustment of nerves controlling the lower urinary tract and pelvic floor. The gastric cancer market is becoming quickly because of expanding occurrence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors over the globe. Significant drivers for the Gastric Cancer Market are treatment progressions, combination therapies, expanding the number of growth treatment focuses, the extensive number of regulatory approvals for metastatic gastric disease and low-measurement radiation innovation-based devices.
Moreover, the introduction of novel treatments for metastatic stomach disease is relied upon to drive the development of the Gastric Cancer market soon. However, the absence of sufficient monetary help from medical coverage strategies and stringent regulatory framewok for approving complex nature of radiation devices are the main considerations that can hamper the stomach malignancy advertise development over the figure time frame. Different factors, like, high cost of therapy and monetarily less accessibility of medications for the treatment of Gastric Cancer may hamper the worldwide high cost of therapy.
Study Period
2024-2030Base Year
2023CAGR
15.3%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Currently, the products available in the market constitutes of a broad assortment of treatment choices, for example, angiogenesis inhibitors, new chemotherapies and HER2-focused on therapy. The worldwide gastric cancer treatment market is becoming quickly attributable to the high extent of people with gastric cancer and the nearness of a solid medication pipeline. To pick up footing in this market, the sellers are assembling and marketing gastric cancer drugs hat display a high wellbeing and adequacy profile, this causes the merchants to pick up a focused edge over their peers. In February 2018, Imugene, an invulnerable oncology organization declared that its malignancy immunization yields promising outcomes in gastric disease clinical preliminary examinations and in September 2017, The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab (Keytruda®) to be utilized on patients with cutting edge gastric cancer growth.
By Treatment Type
By Cancer Type
By End User
The gastric cancer treatment market size was valued at USD 9.5 billion in 2023
Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Hoffmann-La Roche Ltd, Pfizer, Inc.
North America is the fastest-growing region for gastric cancer treatment market
1.Executive Summary |
2.Global Gastric Cancer Treatment Market Introduction |
2.1.Global Gastric Cancer Treatment Market - Taxonomy |
2.2.Global Gastric Cancer Treatment Market - Definitions |
2.2.1. By Treatment Type |
2.2.2. By Cancer Type |
2.2.3. By End User |
2.2.4. By Region |
3.Global Gastric Cancer Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Gastric Cancer Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Gastric Cancer Treatment Market By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Chemotherapy |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Adjuvant Chemotherapy |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Radiation Therapy |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Surgery |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Targeted Therapy |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Gastric Cancer Treatment Market By Cancer Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Laryngeal Cancer |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Lip and Oral Cavity Cancer |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Nasopharyngeal Cancer |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Oropharyngeal Cancer |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Salivary Gland Cancer |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global Gastric Cancer Treatment Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Clinics |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Ambulatory Surgical Centers |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Specialized Cancer Treatment Centers |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Gastric Cancer Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Gastric Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Chemotherapy |
9.1.2.Adjuvant Chemotherapy |
9.1.3.Radiation Therapy |
9.1.4.Surgery |
9.1.5.Targeted Therapy |
9.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Laryngeal Cancer |
9.2.2.Lip and Oral Cavity Cancer |
9.2.3.Nasopharyngeal Cancer |
9.2.4.Oropharyngeal Cancer |
9.2.5.Salivary Gland Cancer |
9.2.6.Others |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Clinics |
9.3.3.Ambulatory Surgical Centers |
9.3.4.Specialized Cancer Treatment Centers |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Gastric Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Chemotherapy |
10.1.2.Adjuvant Chemotherapy |
10.1.3.Radiation Therapy |
10.1.4.Surgery |
10.1.5.Targeted Therapy |
10.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Laryngeal Cancer |
10.2.2.Lip and Oral Cavity Cancer |
10.2.3.Nasopharyngeal Cancer |
10.2.4.Oropharyngeal Cancer |
10.2.5.Salivary Gland Cancer |
10.2.6.Others |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Clinics |
10.3.3.Ambulatory Surgical Centers |
10.3.4.Specialized Cancer Treatment Centers |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Gastric Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Chemotherapy |
11.1.2.Adjuvant Chemotherapy |
11.1.3.Radiation Therapy |
11.1.4.Surgery |
11.1.5.Targeted Therapy |
11.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Laryngeal Cancer |
11.2.2.Lip and Oral Cavity Cancer |
11.2.3.Nasopharyngeal Cancer |
11.2.4.Oropharyngeal Cancer |
11.2.5.Salivary Gland Cancer |
11.2.6.Others |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Clinics |
11.3.3.Ambulatory Surgical Centers |
11.3.4.Specialized Cancer Treatment Centers |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Gastric Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Chemotherapy |
12.1.2.Adjuvant Chemotherapy |
12.1.3.Radiation Therapy |
12.1.4.Surgery |
12.1.5.Targeted Therapy |
12.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Laryngeal Cancer |
12.2.2.Lip and Oral Cavity Cancer |
12.2.3.Nasopharyngeal Cancer |
12.2.4.Oropharyngeal Cancer |
12.2.5.Salivary Gland Cancer |
12.2.6.Others |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Clinics |
12.3.3.Ambulatory Surgical Centers |
12.3.4.Specialized Cancer Treatment Centers |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Gastric Cancer Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Chemotherapy |
13.1.2.Adjuvant Chemotherapy |
13.1.3.Radiation Therapy |
13.1.4.Surgery |
13.1.5.Targeted Therapy |
13.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Laryngeal Cancer |
13.2.2.Lip and Oral Cavity Cancer |
13.2.3.Nasopharyngeal Cancer |
13.2.4.Oropharyngeal Cancer |
13.2.5.Salivary Gland Cancer |
13.2.6.Others |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Clinics |
13.3.3.Ambulatory Surgical Centers |
13.3.4.Specialized Cancer Treatment Centers |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Abbott Laboratories, Inc.(U.S) |
14.2.2.AstraZeneca plc (U.K) |
14.2.3.Eli Lilly and Company(U.S.) |
14.2.4.Hoffmann-La Roche Ltd. (Switzerland) |
14.2.5.Pfizer, Inc. (U.S.) |
14.2.6.GlaxoSmithKline plc (UK) |
14.2.7.Amgen, Inc.(U.S) |
14.2.8.Celgene corporation (U.S) |
14.2.9.Novartis AG (Switzerland) |
15. Research Methodology |
16. Appendix and Abbreviations |